Developmental neurogenetic diseases can only be studied, and potentially treated, once systems to predictably deliver and express genes in neuronal cells are developed. We have utilized herpes simplex virus (HSV) as a vector for expressing genes in neuronal cells. This human DNA virus, for which about 90 percent of the U.S. population is seropositive, forms latent infections which persist for the lifetime of the individual. Using HSV derived vectors, we will study the nervous system component of lysosomal storage disease. Lysosomal storage in neurons results in severe mental retardation in most children with these diseases. Specifically, we will use a Beta-glucuronidase-negative-mouse (gusmps/gusmps), with mucopolysaccharidosis (MPS) type VII (Sly disease) as an animal model. During the previous grant period we demonstrated that a recombinant HSV vector with a Beta-glucuronidase gene under control of the only viral promoter, that is active during latency (LAT promoter), could move from the periphery to the central nervous system. By using this promoter we achieved long term expression of the corrected gene in the nervous system of diseased mice. We noted several problems, including lower than expected numbers of latently infected cells, discordant enzyme levels relative to mRNA levels, and hightened pathogenesis in mutant compared to normal mice. We have developed vector strains of HSV suitable for direct intercranial inoculation into CNS and examined their pathogenesis. We now wish to continue our studies by examining the factors that increase GUSB activity in neuronal cells, and increase the number of corrected cells, to bring vector correction to a level that will change the clinical disease. Specifically, this will be achieved by examining various chimeric LAT-GUSB genes for their ability to express both at the RNA and the translational level in the context of latent HSV. The goal of these studies is to address the problem of treatment of neurogenetic diseases by developing a method of expressing genes in the nervous system in vivo using a ubiquitous human virus. These studies will also provide a method for studying gene regulation in neuronal cells in vivo using the state of the art techniques of molecular biology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS029390-09
Application #
6126230
Study Section
Special Emphasis Panel (ZRG1-MDCN-6 (01))
Program Officer
Spinella, Giovanna M
Project Start
1991-04-07
Project End
2002-11-30
Budget Start
1999-12-01
Budget End
2000-11-30
Support Year
9
Fiscal Year
2000
Total Cost
$298,840
Indirect Cost
Name
University of Pennsylvania
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Liu, Wenpei; Griffin, Gerald; Clarke, Trena et al. (2015) Bilateral single-site intracerebral injection of a nonpathogenic herpes simplex virus-1 vector decreases anxiogenic behavior in MPS VII mice. Mol Ther Methods Clin Dev 2:14059
Volcy, Ketna; Fraser, Nigel W (2013) DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line. J Neurovirol 19:57-64
Simonato, Michele; Bennett, Jean; Boulis, Nicholas M et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:277-91
Husain, T; Passini, M A; Parente, M K et al. (2009) Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters. Gene Ther 16:927-32
Wolfe, John H (2009) Gene therapy in large animal models of human genetic diseases. Introduction. ILAR J 50:107-11
Berges, Bradford K; Wolfe, John H; Fraser, Nigel W (2007) Transduction of brain by herpes simplex virus vectors. Mol Ther 15:20-9
Berges, Bradford K; Yellayi, Srikanth; Karolewski, Brian A et al. (2006) Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing beta-glucuronidase. Mol Ther 13:859-69
Berges, B K; Wolfe, J H; Fraser, N W (2005) Stable levels of long-term transgene expression driven by the latency-associated transcript promoter in a herpes simplex virus type 1 vector. Mol Ther 12:1111-9
Kang, Wen; Mukerjee, Ruma; Fraser, Nigel W (2003) Establishment and maintenance of HSV latent infection is mediated through correct splicing of the LAT primary transcript. Virology 312:233-44
Heuer, Gregory G; Passini, Marco A; Jiang, Kanli et al. (2002) Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol 52:762-70

Showing the most recent 10 out of 25 publications